NKTR Valuation Metrics
FCF$-209.38M
FCF Growth Rate—
EPS Growth (CAGR)—
WACC10.00%
Nektar Therapeutics
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in one Phase 2b clinical trial in atopic dermatitis, one Phase 2b clinical trial in alopecia areata, and in one Phase 2 clinical trial in Type 1 diabetes mellitus. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar is headquartered in San Francisco, California.
Current Price
$70.62
-4.99%Profile
Valuation (TTM)
Market Cap$2.03B
P/E-12.81
EV—
P/B22.55
Shares Out28.69M
P/Sales36.42
Revenue$55.63M
EV/EBITDA—
Nektar Therapeutics (NKTR) Valuation
Fair Value Models
Graham Number, PEG-based, and Earnings-based models
View Fair Value →NKTR Valuation & Fair Value Analysis
Nektar Therapeutics (NKTR) valuation analysis using multiple fair value methodologies. GoodMoat calculates a blended fair value target using discounted cash flow (DCF) analysis, the Graham Number, and earnings-based valuation models.
The price-to-earnings (P/E) ratio is -12.81. Price-to-book ratio is 22.55. Price-to-sales ratio is 36.42. PEG ratio is 0.26.
GoodMoat's valuation models include the Graham Number (based on EPS and book value), an earnings-based model (discounted future EPS), and a PEG-adjusted valuation. The three models are averaged to produce a blended fair value estimate. Use these tools alongside the DCF calculator and reverse DCF to form a comprehensive view of Nektar Therapeutics's intrinsic value.